GBT 440-031 A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease

Project: Research project

Project Details

StatusActive
Effective start/end date6/1/175/31/22

Funding

  • Global Blood Therapeutics, Inc.